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Abstract
Neuroplasticity in the central nucleus of the amygdala (CeA), particularly its latero-capsular division (CeLC), is an
important contributor to the emotional-affective aspects of pain. Previous studies showed synaptic plasticity of
excitatory transmission to the CeLC in different pain models, but pain-related changes of inhibitory transmission
remain to be determined. The CeLC receives convergent excitatory inputs from the parabrachial nucleus in the
brainstem and from the basolateral amygdala (BLA). In addition, feedforward inhibition of CeA neurons is driven by
glutamatergic projections from the BLA area to a cluster of GABAergic neurons in the intercalated cell masses (ITC).
Using patch-clamp in rat brain slices we measured monosynaptic excitatory postsynaptic currents (EPSCs) and poly-
synaptic inhibitory currents (IPSCs) that were evoked by electrical stimulation in the BLA. In brain slices from
arthritic rats, input-output functions of excitatory synaptic transmission were enhanced whereas inhibitory synaptic
transmission was decreased compared to control slices from normal untreated rats. A non-NMDA receptor antago-
nist (NBQX) blocked the EPSCs and reduced the IPSCs, suggesting that non-NMDA receptors mediate excitatory
transmission and also contribute to glutamate-driven feed-forward inhibition of CeLC neurons. IPSCs were blocked
by a GABAA receptor antagonist (bicuculline). Bicuculline increased EPSCs under normal conditions but not in slices
from arthritic rats, which indicates a loss of GABAergic control of excitatory transmission. A metabotropic glutamate
receptor subtype 1 (mGluR1) antagonist (LY367385) reversed both the increase of excitatory transmission and the
decrease of inhibitory transmission in the arthritis pain model but had no effect on basal synaptic transmission in
control slices from normal rats. The inhibitory effect of LY367385 on excitatory transmission was blocked by bicu-
culline suggesting the involvement of a GABAergic mechanism. An mGluR5 antagonist (MTEP) inhibited both exci-
tatory and inhibitory transmission in slices from normal and from arthritic rats. The analysis of spontaneous and
miniature EPSCs and IPSCs showed that mGluR1 acted presynaptically whereas mGluR5 had postsynaptic effects. In
conclusion, mGluR1 rather than mGluR5 can account for the pain-related changes of excitatory and inhibitory
synaptic transmission in the CeLC through a mechanism that involves inhibition of inhibitory transmission
(disinhibition).
Background
Pain has a strong emotional component and is signifi-
cantly associated with anxiety and depression. The
amygdala plays a key role in emotional learning and
memory as well as in affective disorders [1-4] and is
also important for the emotional-affective dimension of
pain and pain modulation [5-8]. Pharmacologic inhibi-
tion of amygdala hyperactivity has been shown to
decrease nocifensive and affective responses in animal
pain models [5,8-13]. Conversely, pharmacologic activa-
tion can produce pain behavior even in the absence of
tissue injury [14-17].
The amygdala consists of several anatomically and
functionally distinct nuclei [2,18]. The laterocapsular
division of the central nucleus (CeLC) has been termed
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tive-specific information from the spinal cord and brain-
stem (external parabrachial area, PB) and the vast
majority of CeLC neurons respond exclusively or prefer-
entially to noxious stimuli [5,8,19]. Synaptic plasticity of
PB inputs to the CeLC has been shown in models of
arthritic pain [20-23], visceral pain [24] and chronic
neuropathic pain [25] and is associated with pain-related
central sensitization of CeLC neurons [21,26-31]. Highly
processed multimodal, including nociceptive, informa-
tion reaches the CeLC from thalamus and cortex
through the lateral-basolateral (LA-BLA) network [5,8].
The LA-BLA circuitry is critical for the emotional eva-
luation of sensory stimuli and for acquisition and conso-
lidation of aversive associations [2,3,32,33]. Our previous
studies showed pain-related synaptic plasticity of excita-
tory transmission at the LA-BLA and BLA-CeLC
synapses [10,20,23]. The BLA can influence CeA pro-
cesses via direct glutamatergic projections and through
indirect disynaptic routes involving GABAergic neurons
in the intercalated cell masses (ITC) that project to the
CeA [2,32,34]. Activation of inhibitory ITC neurons and
subsequent inhibition of CeA neurons has been sug-
gested to play an important role in fear extinction
[2,35]. However, the role of synaptic inhibition of CeLC
neurons in pain-related plasticity remains to be deter-
mined and was addressed in this study.
Another focus of this study was on the involvement of
group I metabotropic glutamate receptors (mGluRs) in
synaptic inhibition of CeLC neurons, because our pre-
vious studies showed that these receptors are important
modulators of excitatory synaptic transmission in the
CeLC [20]. Group I mGluRs comprise mGluR1 and
mGluR5 subtypes and are involved in neuroplasticity
associated with normal brain functions as well as in
neurological and psychiatric disorders [36-39] and in
pain mechanisms [40-42]. Group I mGluRs play a criti-
cal role in pain-related central sensitization of amygdala
neurons [20,27] and in amygdala-mediated pain beha-
viors [9,15,43]. Using patch-clamp recordings in brain
slices from arthritic rats (kaolin-carrageenan model) and
from controls, we measured and compared pain-related
changes in inhibitory and excitatory transmission from
the BLA to the CeLC and the contribution of group I
mGluRs to these changes.
Results
Pain-related increase of excitatory transmission and
decrease of glutamate-driven inhibitory transmission in
CeLC neurons
Excitatory and inhibitory postsynaptic currents (EPSCs
and IPSCs, respectively) were evoked in CeLC neurons
by electrical stimulation in the BLA (Figure 1A and 1B).
Monosynaptic EPSCs recorded in voltage-clamp at
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Figure 1 Monosynaptic excitatory and polysynaptic inhibitory
synaptic transmission in CeLC neurons.( A) Coronal brain slices
containing the right amygdala were obtained from normal rats and
arthritic rats 4-6 h after injections of kaolin and carrageenan (K/C)
into the left knee joint. Magnified area shows position of the patch-
clamp electrode ("Recording”) in the CeLC; stimulation electrode in
the BLA to activate direct glutamatergic projections and indirect
disynaptic connections that involve GABAergic neurons in the
intercalated cell masses (ITC). Diagrams are from [66]. (B) Biphasic
synaptic responses were evoked at different holding potentials (-70,
-30, and 0 mV). (C) Individual traces (average of 8-10) of synaptic
responses evoked at -70 mV (downward deflections, EPSCs;
inhibited by NBQX, 10 μM) and at 0 mV (upward deflections, IPSCs;
blocked by bicuculline, 10 μM). Scale bars, 50 pA, 30 ms. (D)
Monosynaptic EPSCs, but not polysynaptic IPSCs, follow high-
frequency stimulation (20 Hz; 6 individual traces each). Scale bars, 50
pA, 30 ms. (E) Individual EPSCs and IPSCs evoked with twice-
threshold stimulation (30 sweeps each). Latencies of IPSCs were
longer and more variable. Calibration: 50 pA, 3 ms. (F) Distribution
of EPSC and IPSC latencies measured from stimulus artifact to onset
of synaptic current in one neuron (n = 100 events). (G) Bar
histograms show average latencies (means ± SE) of EPSCs and IPSCs
in 10 neurons. ** P < 0.01, paired t-test. (H) Bar histograms show
the number of neurons that did not respond to the second or third
high-frequency stimulus (HFS, 20 Hz). The failure rate is normalized
for each neuron and averaged across the sample of neurons (n =
15; 0, no failure; 1, no IPSC). ** P < 0.01, compared to 1
st stimulus
(no failure), Dunnett’s multiple comparison test.
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b e c a u s et h e yw e r ec o m p l e t e l yb l o c k e db yN B Q X( 1 0
μM, Figure 1C). IPSCs recorded at 0 mV holding poten-
tial were blocked by a GABAA receptor antagonist
(bicuculline, 10 μM, Figure 1C). EPSCs, but not IPSCs,
followed high-frequency (20 Hz) synaptic stimulation
reliably (Figure 1D). EPSCs had a fixed latency whereas
the latencies of IPSCs showed larger variability (Figure
1E and 1F). Average latency of EPSCs (from stimulus
artifact to onset of synaptic current) was significantly
shorter than that of IPSCs (see individual example in
Figure 1F; data are summarized in Figure 1G, n = 10
neurons; P < 0.01, paired t-test). Failure to follow high-
frequency synaptic stimulation was significant in the
sample of neurons (n = 15; P < 0.01, Dunnett’s multiple
comparison test, Figure 1H). The data show that CeLC
neurons receive monosynaptic excitatory and polysynap-
tic inhibitory inputs from the BLA.
To determine pain-related changes of excitatory and
inhibitory synaptic inputs, input-output (I/O) relation-
ships were obtained by measuring peak amplitudes of
EPSCs and IPSCs as a function of afferent fiber stimulus
intensity for each neuron (see examples in Figure 2A
and 2B). CeLC neurons were recorded in slices from
normal untreated rats and in slices from arthritic rats
(4-6 hr after induction of arthritis in one knee joint; see
Methods). Compared with controls (n = 11 neurons), I/
O function of monosynaptic EPSCs at the BLA-CeLC
synapse increased significantly in the arthritis pain
model (n = 12 neurons, F1,231 = 30.49, P < 0.0001, main
effect of treatment, two-way ANOVA; Figure 2A),
whereas the I/O function of IPSCs decreased signifi-
cantly (control, n = 11 neurons; arthritis, n = 12 neu-
rons; F1,231 = 22.15, P < 0.0001, main effect of
treatment, two-way ANOVA; Figure 2B). The increase
of excitatory transmission relative to inhibitory trans-
mission in the arthritis pain model is reflected in the
significantly increased EPSC/IPSC ratio (P < 0.001,
unpaired t test; Figure 2C).
Next we tested the hypothesis that polysynaptic inhibi-
tory transmission is glutamate- driven. IPSCs were
inhibited by a non-NMDA receptor antagonist (NBQX,
10 μM; Figure 3) in slices from normal animals (n = 5
neurons, F1,88 = 24.11, P < 0.0001, main effect of drug,
two-way ANOVA; Figure 3A) and in slices from
arthritic rats (n = 5 neurons, F1,88 = 36.18, P < 0.0001,
main effect of drug, two-way ANOVA; Figure 3B). The
effect of NBQX on I/O functions of inhibitory transmis-
sion was not significantly different in arthritis compared
to normal conditions (P > 0.05, unpaired t-test; Figure
3C). The pharmacological profile (blockade by NBQX)
and synaptic characteristics (longer and more variable
latencies and inability to follow high-frequency stimula-
tion) indicate that IPSCs recorded in CeLC neurons are
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Figure 2 Increased excitatory and decreased inhibitory
transmission in CeLC neurons in a model of arthritic pain.( A)
Input-output (I/O) functions of monosynaptic EPSCs (recorded at -70
mV) increased significantly (P < 0.0001, two-way ANOVA, see
Results) in slices from arthritis rats (n = 12 neurons) compared with
control slices from normal rats (n = 11 neurons). Traces show EPSCs
evoked with stimulus intensities of 0.3, 0.6 and 0.9 mA in one CeLC
neuron from a normal rat and in another CeLC neuron from an
arthritic rat. Scale bars, 50 pA, 10 ms. (B) I/O function of IPSCs
(recorded at 0 mV) decreased significantly (P < 0.0001, two-way
ANOVA, see Results) in slices from arthritic rats (n = 12 neurons)
compared with slices from normal rats (n = 11 neurons). Individual
traces show IPSCs evoked with stimulation intensities of 0.3, 0.6 and
0.9 mA. Scale bars, 50 pA, 10 ms. (C) The ratio of EPSCs and IPSCs
evoked with a stimulation intensity of 1 mA increased significantly
in slices from arthritic rats (n = 12 neurons) compared to controls
(n = 11 neurons). *** P < 0.001, unpaired t-test. (A-C) Symbols and
error bars represent means ± SE.
Ren and Neugebauer Molecular Pain 2010, 6:93
http://www.molecularpain.com/content/6/1/93
Page 3 of 14polysynaptic, involving a glutamatergic synapse. The
results are consistent with morphological and functional
evidence for glutamatergic projections from the BLA to
GABAergic interneurons in the ITC [2,35] and suggest
that CeLC neurons receive disynaptic feedforward
inhibition.
Pain-related loss of GABAergic inhibition of excitatory
transmission
We sought to determine if feedforward inhibition of
CeLC neurons modulates excitatory synaptic transmis-
sion from the BLA and if that effect changes in the
arthritis pain state. A GABAA receptor antagonist (bicu-
culline, 10 μM) significantly increased I/O function of
excitatory transmission at the BLA-CeLC synapse under
normal conditions (n = 5 neurons, F1,88 = 8.80, P < 0.01,
main effect of drug, two-way ANOVA; Figure 4A), sug-
gesting GABAergic control of excitatory inputs to the
CeLC. In slices from arthritic rats, however, bicuculline
had no significant effect on EPSCs evoked in CeLC neu-
rons (n = 5 neurons, F1,88 = 2.67, P > 0.05, main effect
of drug, two-way ANOVA; Figure 4B). The significantly
decreased facilitatory effect of bicuculline in the arthritis
model (P < 0.05, unpaired t-test; Figure 4C) may suggest
that loss of inhibition contributes at least in part to the
pain-related increase of excitatory transmission (see
Figure 2A).
mGluR1, but not mGluR5, can account for the pain-
related changes of excitatory and inhibitory transmission
in CeLC neurons
Our previous studies showed that mGluR1 and mGluR5
modulate excitatory transmission in the CeLC and upre-
gulation of mGluR1 is associated with pain-related
synaptic plasticity [20]. Here we examined the modula-
tion of inhibitory transmission by mGluR1 and mGluR5.
Confirming the results of our previous study obtained
with a different mGluR1 antagonist (CPCCOEt) [20], a
selective mGluR1 antagonist (LY367385, 10 μM) inhib-
ited excitatory synaptic transmission in CeLC neurons in
slices from arthritic rats (n = 5 neurons, F1,88 = 37.10, P <
0.0001, main effect of drug, two-way ANOVA; Figure 5B)
b u th a dn os i g n i f i c a n te f f e c tunder normal conditions
(n = 3 neurons, F1,44 = 1.03, P > 0.05, main effect of drug,
t w o - w a yA N O V A ;F i g u r e5 A ) .T h ei n h i b i t o r ye f f e c to f
LY367385 in the pain model was significantly different
from that under normal conditions (P < 0.05, unpaired
t-test; Figure 5C). LY367385 increased inhibitory synaptic
transmission in slices from arthritic rats significantly (n =
5n e u r o n s ,F 1,88 = 15.91, P < 0.0001, main effect of drug,
two-way ANOVA; Figure 5E) but had no significant
effect under normal conditions (n = 3 neurons, F1,44 =
0.56, P > 0.05, main effect of drug, two-way ANOVA;
Figure 5D). The facilitatory effect of LY367385 in the
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Figure 3 Inhibitory transmission onto CeLC neurons is driven
by non-NMDA receptors.( A) A non-NMDA receptor antagonist
(NBQX, 10 μM) decreased input-output (I/O) functions of IPSCs
(recorded at 0 mV) in slices from normal rats significantly (n = 5
neurons, P < 0.0001, two-way ANOVA; see Results). Traces show
IPSCs evoked in one CeLC neuron before (Predrug) and during
NBQX. Stimulus intensity, 0.9 mA; scale bars, 50 pA, 10 ms. (B) NBQX
also decreased I/O function of IPSCs (recorded at 0 mV) in slices
from arthritic rats (n = 5 neurons) significantly (n = 5 neurons, P <
0.0001, two-way ANOVA; see Results). Individual traces show IPSCs
evoked in one CeLC neuron before (Predrug) and during NBQX.
Stimulus intensity, 0.9 mA; scale bars, 50 pA, 10 ms. (C) The effect of
NBQX normalized to predrug values (set to 1.0) was not significantly
different between slices from arthritic rats and normal controls (P >
0.05, unpaired t-test). (A-C) Symbols and error bars represent
means ± SE.
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Page 4 of 14pain state was significantly different from that under nor-
mal conditions (P < 0.05, unpaired t-test; Figure 5F). The
results show that LY367385 can reverse pain-related
changes of excitatory as well as inhibitory transmission in
the CeLC.
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Figure 4 GABAergic inhibition is lost in a model of arthritic
pain.( A) A GABAA receptor antagonist (bicuculline, 10 μM)
significantly increased I/O function of EPSCs evoked in CeLC
neurons in slices from normal rats (n = 5 neurons, P < 0.001, two-
way ANOVA; see Results). Individual traces show EPSCs evoked in
one CeLC before (Predrug) and during bicuculline. Stimulus
intensity, 0.9 mA. Scale bars: 50 pA, 10 ms. (B) Bicuculline had no
significant effect on EPSCs recorded in CeLC neurons in slices from
arthritic rats (n = 5 neurons, P > 0.05, two-way ANOVA; see Results).
Traces show EPSCs recorded in one CeLC neuron before (Predrug)
and during bicuculline; they were nearly identical as bicuculline had
no effect. Stimulus intensity, 0.9 mA; scale bars, 50 pA, 10 ms. (C)
Bar histograms show the significantly greater facilitatory effect of
bicuculline on EPSCs (normalized to predrug; set to 1.0) in slices
from normal rats compared to arthritic rats. * P < 0.05, unpaired t-
test. (A-C) Symbols and error bars represent means ± SE.
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Figure 5 Blockade of mGluR1 reverses the pain-related
increase of excitatory transmission and the decrease of
inhibitory transmission in CeLC neurons.( A) A selective mGluR1
antagonist (LY367385, 10 μM) had no significant effect on I/O
functions of EPSCs at the BLA-CeLC synapse in slices from normal
rats (n = 3 neurons, P > 0.05, two-way ANOVA; see Results). (B)
LY367385 inhibited excitatory transmission in slices from arthritic
rats (n = 5 neurons, P < 0.0001, two-way ANOVA; see Results). (C)
The inhibitory effect of LY367385 (normalized to predrug; set to 1.0)
in the arthritis pain model was significantly different from that
under normal conditions. * P < 0.05, unpaired t-test. (D) LY367385
had no significant effect on I/O functions of IPSCs in slices from
normal rats (n = 3 neurons, P > 0.05, two-way ANOVA; see Results).
(E) LY367385 increased inhibitory transmission in slices from arthritic
rats significantly (n = 5 neurons, P < 0.0001, two-way ANOVA; see
Results). (F) The facilitatory effect of LY367385 (normalized to
predrug; set to 1.0) in the arthritis pain model was significantly
different from that under normal conditions. * P < 0.05, unpaired t-
test. (A-F) Symbols and error bars represent means ± SE.
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antagonist (MTEP, 1 μM) significantly decreased the
input-output functions of excitatory synaptic transmis-
sion in slices from arthritic rats (n = 5 neurons, F1,88 =
16.12, P < 0.0001, main effect of drug, two-way
ANOVA; Figure 6B). Unlike LY367385, however, MTEP
had inhibitory effects in slices from normal rats (n = 5
neurons, F1,88 = 5.75, P < 0.01, main effect of drug, two-
way ANOVA; Figure 6A). The inhibitory effects on exci-
tatory transmission were not significantly different
between arthritis and normal conditions (P > 0.05,
unpaired t-test; Figure 6C). MTEP also decreased inhibi-
tory synaptic transmission in slices from arthritic rats (n
= 5 neurons, F1,88 = 10.13, P < 0.01, main effect of drug,
two-way ANOVA; Figure 6E) and in slices from normal
animals (n = 5 neurons, F1,88 = 22.54, P < 0.0001, main
effect of drug, two-way ANOVA; Figure 6D). The inhi-
bitory effects of MTEP on IPSCs were not significantly
different between normal and arthritis conditions (P >
0.05, unpaired t-test; Figure 6F). The results show that
mGluR5 are involved in excitatory and inhibitory synap-
tic transmission under normal conditions and in the
pain state, whereas mGluR1 contribute only to the pain-
related changes of excitatory and inhibitory transmission
in CeLC neurons.
Presynaptic action potential-dependent action of mGluR1
and postsynaptic action of mGluR5
The analysis of spontaneous and miniature EPSCs and
IPSCs is a well established electrophysiological approach
to determine pre- versus postsynaptic mechanisms. Pre-
synaptic changes at the transmitter release site affect
frequency, whereas changes at the postsynaptic mem-
brane would alter amplitude (quantal size) [44]. In slices
from arthritic rats, LY367385 (10 μM) decreased fre-
quency (Figure 7B), but not amplitude (Figure 7C), of
spontaneous EPSCs (sEPSCs) significantly (cumulative
frequency distribution, P < 0.05, Kolmogorov Smirnov
test; mean frequency, P < 0.01, paired t-test; n = 6 neu-
rons). Original recordings of sEPSCs are shown in
Figure 7A. Recordings were made in slices from arthritic
rats, because LY367385 had no significant effect under
normal conditions (see Figure 5). LY367385 (10 μM)
had no significant effect on frequency (Figure 7E) and
amplitude (Figure 7F) of miniature EPSCs (mEPSCs)
recorded in TTX (1 μM) in slices from arthritic rats
(cumulative distribution, P > 0.05, Kolmogorov-Smirnov
test; mean frequency and amplitude, n = 8 neurons, P >
0.05, paired t-test; original traces are shown in Figure
7D). The lack of effect on mEPSCs suggests an action
potential-dependent site of action. LY367385 (10 μM)
increased frequency, but not amplitude, of sIPSCs (n =
7 neurons; Figure 7G-I) and mIPSCs (n = 7 neurons;
Figure 7J-L) significantly (cumulative frequency distribu-
tion, P < 0.05, Kolmogorov-Smirnov test; mean fre-
quency, P < 0.01, paired t-test). The data suggest that
mGluR1 act presynaptically on GABAergic terminals to
regulate glutamatergic transmission in the arthritis pain
model.
MTEP (10 μM) decreased the amplitude, but not fre-
quency, of sEPSCs (n = 5 neurons; Figure 8A-C) and
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Figure 6 Blockade of mGluR5 inhibits excitatory and inhibitory
transmission under normal conditions and in arthritis.( A)A
selective mGluR5 antagonist (MTEP, 1 μM) decreased I/O functions
of excitatory transmission in slices from normal rats significantly (n =
5 neurons, P < 0.01, two-way ANOVA; see Results). (B) MTEP
inhibited EPSCs in slices from arthritic rats significantly (n = 5
neurons, P < 0.0001, two-way ANOVA; see Results). (C) Normalized
effects (to predrug; set to 1.0) of MTEP on EPSCs were not
significantly between arthritis and normal conditions (P > 0.05,
unpaired t-test). (D) MTEP decreased I/O functions of inhibitory
synaptic transmission in slices from normal animals (n = 5 neurons,
P < 0.0001, two-way ANOVA; see Results). (E) MTEP decreased IPSCs
in slices from arthritic rats significantly (n = 5 neurons, P < 0.01,
two-way ANOVA; see Results). (F) Normalized effects (to predrug; set
to 1.0) of MTEP on IPSCs were not significantly different between
normal and arthritis conditions (P > 0.05, unpaired t-test). (A-F)
Symbols and error bars represent means ± SE.
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Figure 7 Effects of LY367385 on spontaneous and miniature excitatory and inhibitory postsynaptic currents in CeLC neurons from
arthritic rats.( A) Original current traces of spontaneous EPSCs (sEPSC) in an individual CeLC neuron (held at -70 mV) from an arthritic rat
before (Predrug) and during LY367385 (10 μM). (B, C) Cumulative distribution analysis of sEPSC frequency (B) and amplitude (C). LY367385
caused a significant shift toward larger inter-event intervals (lower frequency; P < 0.05, Kolmogorov-Smirnov test). LY367385 decreased mean
sEPSC frequency (B), but not amplitude (C), significantly (n = 6 neurons, P < 0.01, paired t-test). (D) Current traces of miniature EPSCs (mEPSCs)
recorded in the presence of TTX (1 μM) in one CeLC neuron from an arthritic rat before (Predrug) and during LY367385 (10 μM). (E, F) LY367385
(10 μM) had no significant effect on frequency (E) and amplitude (F) of mEPSC (cumulative distribution, P > 0.05, Kolmogorov-Smirnov test;
means ± SE, n = 8 neurons, P > 0.05, paired t-test). (G) Current traces of sIPSCs recorded in one CeLC neuron (held at 0 mV) in a brain slice
from an arthritic rat before (Predrug) and during LY367385 (10 μM). (H, I) LY367385 (10 μM) increased frequency (H), but not amplitude (I), of
sIPSCs significantly (cumulative frequency distribution, P < 0.05, Kolmogorov-Smirnov test; mean frequency, n = 7 neurons, P < 0.01, paired
t-test). (J) Current traces of mIPSCs in the presence of TTX (1 μM) in one CeLC neuron from an arthritic rat before (Predrug) and during
LY367385 (10 μM). (K, L) LY367385 (10 μM) increased frequency (K), but not amplitude (L), of mIPSCs significantly (cumulative frequency
distribution, P < 0.05, Kolmogorov-Smirnov test; mean frequency, n = 7 neurons, P < 0.01, paired t-test). (A, D, G, J) Scale bars, 10 pA, 2 s.
(B, C, E, F, H, I, K, L) Bar histograms show means ± SE.
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Figure 8 Effects of MTEP on spontaneous and miniature excitatory and inhibitory postsynaptic currents in CeLC neurons from
arthritic rats.( A) Original current traces of sEPSCs in an individual CeLC neuron (held at -70 mV) from an arthritic rat before (Predrug) and
during MTEP (1 μM). (B, C) MTEP (1 μM) decreased sEPSC amplitude (C), but not frequency (B), significantly (cumulative amplitude distribution,
P < 0.05, Kolmogorov-Smirnov test; mean amplitude, n = 5 neurons, P < 0.01, paired t-test). (D) Current traces of mEPSCs recorded in the
presence of TTX (1 μM) in one CeLC neuron from an arthritic rat before (Predrug) and during MTEP (1 μM). (E, F) MTEP (1 μM) decreased mEPSC
amplitude (F), but not frequency (E), significantly (cumulative amplitude distribution, P < 0.05, Kolmogorov-Smirnov test; mean amplitude, n = 5
neurons, P < 0.01, paired t-test). (G) Current traces of sIPSCs recorded in one CeLC neuron (held at 0 mV) in a brain slice from an arthritic rat
before (Predrug) and during MTEP (1 μM). (H, I) MTEP (1 μM) decreased amplitude (I), but not frequency (H), of sIPSCs significantly (cumulative
amplitude distribution, P < 0.05, Kolmogorov-Smirnov test; mean amplitude, n = 4 neurons, P < 0.001, paired t-test). (J) Current traces of mIPSCs
in the presence of TTX (1 μM) in one CeLC neuron from an arthritic rat before (Predrug) and during MTEP (1 μM). (K, L) MTEP (1 μM) decreased
amplitude (L), but not frequency (K), of mIPSCs significantly (cumulative amplitude distribution, P < 0.05, Kolmogorov-Smirnov test; mean
amplitude, n = 4 neurons, P < 0.001, paired t-test). (A, D, G, J) Scale bars, 10 pA, 2 s. (B, C, E, F, H, I, K, L) Bar histograms show means ± SE.
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Page 8 of 14mEPSCs (n = 5 neurons; Figure 8D-F) recorded in CeLC
neurons in slices from arthritic rats (cumulative ampli-
tude distribution, P < 0.05, Kolmogorov-Smirnov test;
mean amplitude, P < 0.01, paired t-test). MTEP also
decreased the amplitude (n = 4 neurons; Figure 8G-I),
but not frequency (n = 4 neurons; Figure 8J-L), of
sIPSCs and mIPSCs in CeLC neurons significantly
(cumulative amplitude distribution, P < 0.05, Kolmo-
gorov-Smirnov test; mean amplitude, P < 0.001, paired
t-test). The data suggest that mGluR5 regulate both
excitatory and inhibitory synaptic transmission in CeLC
neurons through a postsynaptic mechanism of action.
Presynaptic modulation of excitatory transmission by
mGluR1 involves GABAA receptors
The data presented so far show that mGluR1 acts presy-
naptically to inhibit GABAergic transmission but also
increases excitatory transmission through an action
potential dependent “presynaptic” mechanism. We
tested the hypothesis that the inhibitory action of
mGluR1 on GABAergic terminals is a mechanism by
which mGluR1 increase excitatory transmission.
LY367385 (10 μM) decreased excitatory synaptic trans-
mission (EPSCs, n = 5 neurons, F1,88 = 42.06, P <
0.0001, main effect of drug, two-way ANOVA; Figure
9A) and the number of synaptically evoked spikes (n =
5 neurons, P < 0.05, ANOVA with Bonferroni posttest;
Figure 9B) in CeLC neurons in slices from arthritic rats.
The addition of bicuculline (10 μM) partially reversed
the inhibitory effect of LY367385 on EPSCs (n = 5 neu-
rons, F1,88 = 14.85, P < 0.001, main effect of drug, two-
way ANOVA; Figure 9A) and on synaptically evoked
spikes (n = 5 neurons, P < 0.05, ANOVA with Bonfer-
roni posttest; Figure 9B), whereas bicuculline alone had
no effect in the arthritis pain state (see Figure 4B). The
data suggest that removal of the mGluR1-mediated
blockade of inhibitory transmission with an mGluR1
antagonist restores inhibitory control of excitatory
synaptic transmission as is evident from the facilitatory
effect of a GABAA-receptor antagonist that was lost in
the arthritis pain model. Therefore, activation of
mGluR1 in arthritis may explain the loss of inhibitory
control (disinhibition) of excitatory transmission in the
CeLC.
Monosynaptic IPSCs are not under control of mGluR1 in
the arthritis pain model
IPSCs evoked in some CeLC neurons showed little varia-
bility in latency and followed high-frequency stimulation,
suggesting that they were monosynaptic (Figure 10A and
10B). NBQX (10 μM) had no significant effect on mono-
synaptic IPSCs (n = 3 neurons, P > 0.05, paired t-test;
Figure 10C). In contrast to its facilitatory effect on poly-
synaptic IPSCs associated with feedforward inhibition of
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Figure 9 Blockade of mGluR1 restores facilitatory effects of
bicuculline on excitatory transmission in the arthritis pain
model.( A) LY367385 (10 μM) decreased I/O function of excitatory
synaptic transmission significantly (n = 5 neurons, P < 0.0001, main
effect of drug, two-way ANOVA; see Results). Coapplication of
bicuculline (10 μM) partially reversed the inhibitory effect of
LY367385 (n = 5 neurons, P < 0.001, main effect of drug, two-way
ANOVA; see Results). Current traces of EPSCs recorded in one CeLC
neuron in a brain slice from an arthritic rat before (Predrug) and
during application of LY367385 alone and together with bicuculline.
Scale bars, 50 pA, 10 ms. (B) Current-clamp recordings show that
LY367385 (10 μM) decreased the number of synaptically evoked
action potentials in CeLC neurons in slices from arthritic rats (n = 5
neurons, P < 0.05, ANOVA with Bonferroni posttest). The addition of
bicuculline (10 μM) partially reversed the inhibitory effect of
LY367385 (n = 5 neurons, P < 0.05, ANOVA with Bonferroni
posttest). Bar histograms show the number of spikes per 10 synaptic
stimuli at near-threshold stimulus intensity averaged across the
sample of neurons. Original traces show action potentials and
excitatory postsynaptic potentials evoked in an individual CeLC
neuron in a slice from an arthritic rat. Scale bars, 20 mV, 5 ms. (A, B)
Symbols and error bars represent means ± SE.
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Page 9 of 14CeLC neurons (Figure 5E and 5F), LY367385 (10 μM)
had no significant effect on monosynaptic IPSCs in slices
from arthritic rats (n = 3 neurons, P > 0.05, paired t-test;
Figure 10D). The origin of these monosynaptic inhibitory
inputs remains to be determined.
Discussion
The novel key findings of this study on amygdala func-
tion related to pain are as follows. 1) In contrast to the
increase in excitatory synaptic transmission, inhibitory
feedforward inhibition of CeLC neurons decreases in a
model of arthritis pain, shifting the balance toward a
dominance of excitatory inputs. 2) The differential
change of excitatory and inhibitory transmission
involves mGluR1 acting presynaptically on GABAergic
terminals to decrease inhibitory and enhance excitatory
transmission. 3) Postsynaptic mGluR5 contribute to
both excitatory and inhibitory synaptic transmission
under normal conditions and in the arthritis pain
model; their effect on synaptic inputs does not change
in the pain state. To conclude, the data confirm the
results of our previous studies [20,27] that a change in
the function of mGluR1 rather than mGluR5 contributes
to enhanced excitatory transmission and increased activ-
ity of CeLC neurons; importantly, the present study pro-
vides novel insight into underlying mechanism by
showing that mGluR1 exert their facilitatory effect
through disinhibition, i.e., inhibition of inhibitory con-
trol of excitatory inputs to the CeLC (see Figure 11).
The conclusion is supported by the following observa-
tions. We show for the first time a change in feedfor-
ward inhibition of CeLC neurons in a pain model.
Pharmacological evidence (blockade by NBQX) and
synaptic characteristics (longer and more variable laten-
cies and inability to follow high-frequency stimulation
reliably) indicate that synaptic inhibition of CeLC neu-
rons is polysynaptic, involving a glutamatergic synapse.
The results are consistent with reports in the literature
that glutamatergic projections from the BLA do not
only reach the CeA directly but also target a cluster of
GABAergic interneurons in the ITC that are interposed
between BLA and CeA [2,18,35,45,46]. The CeA serves
as the output nucleus for major amygdala functions and
regulates behavioral responses through projections to
hypothalamic nuclei and brainstem areas [4,45,47]. The
CeA receives affect-related information that is generated
in the LA-BLA network through associative processes
[3,4,18,32]. BLA axons projecting toward the CeA form
excitatory synapses with ITC neurons that project to the
CeA where they generate feed-forward inhibition
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Figure 10 Blockade of mGluR1 has no effect on monosynaptic
IPSCs in the arthritis pain model.( A, B) Individual traces of
monosynaptic IPSCs recorded in one CeLC neuron at 0 mV show
little variability in latency (10 sweeps) and follow high-frequency
stimulation (20 Hz, 6 sweeps). Scale bars 50 pA, 10 ms. (C) NBQX (10
μM) had no significant effect on monosynaptic IPSCs (n = 3
neurons; P > 0.05, paired t-test). (D) LY367385 (10 μM) had no
significant effect on monosynaptic IPSCs (n = 3 neurons; P > 0.05,
paired t-test). (C, D) Individual traces show monosynaptic IPSCs
before (Predrug) and during drug application. Stimulus intensity, 0.9
mA; scale bars, 50 pA, 10 ms. Bar histograms show means ± SE.
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Figure 11 Proposed circuitry. CeLC neurons receive direct
excitatory input from the lateral-basolateral (BLA) nuclei that
contains highly processed multimodal, including nociceptive,
information [5,8]. ITC cells provide inhibitory inputs that contact
CeLC directly, acting on GABAA receptors, but also regulate
glutamatergic inputs to the CeLC. Presynaptic mGluR1 inhibit
GABAergic afferents. In the pain state, increased glutamatergic
transmission to the CeLC activates not only postsynaptic mGluR5
but also presynaptic mGluR1 that inhibit GABAergic transmission.
BLA, basolateral amygdala; ITC, intercalated cell masses; CeLC, latero-
capsular division of the central nucleus of the amygdala; GABA
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Page 10 of 14[45,48,49]. Accumulating evidence suggests that direct
glutamatergic projections from the BLA to the CeA are
important for fear expression whereas activation of ITC
neurons that inhibit CeA output neurons might account
for the reduction of fear expression after extinction
[2,35,50,51].
Our results show that feedforward inhibition controls
excitatory inputs to the CeA under normal conditions
but not in a pain state. The fact that bicuculline
enhanced excitatory transmission while the CeLC neu-
ron was held at -70 mV, the equilibrium potential for
chloride ions, may suggest that GABAA-receptors mod-
ulate excitatory inputs indirectly through a “presynaptic”
site of action or in the network rather than on the
CeLC neuron itself. The significantly decreased facilita-
tory effect of bicuculline in the arthritis model suggests
that a loss of inhibition that may contribute at least in
part to the pain-related increase of excitatory transmis-
sion mediated by mGluR1.
The results obtained with highly selective antagonists
for mGluR1 and mGluR5 [40,42,52,53] show that presy-
naptic mGluR1, but not postsynaptic mGluR5, can
account for the pain-related changes of excitatory and
inhibitory transmission in CeLC neurons. The interac-
tion between mGluR1 and GABAergic transmission
further suggests that pain-related decrease of inhibitory
transmission is an active process that involves activation
of mGluR1. Based on the analysis of spontaneous and
miniature synaptic events, mGluR1 act presynaptically
on GABAergic inputs whereas their effect on excitatory
transmission is indirect through a process that requires
action potential dependent network activity. Excitatory
transmission is under GABAergic inhibition that is lost
in arthritis through a mechanism that involves mGluR1.
Removal of the mGluR1-mediated blockade of inhibitory
transmission with an mGluR1 antagonist restores inhibi-
tory control of excitatory synaptic transmission. There-
fore, activation of mGluR1 that is seen in arthritis but
not under normal conditions may explain the loss of
inhibitory control (disinhibition) of excitatory transmis-
sion in the CeLC.
Group I mGluR subtypes mGluR1 and mGluR5 play
important roles in physiological neuroplasticity as well
as in neurological and psychiatric disorders [36-39] and
in pain mechanisms [40-42]. Our previous studies
showed that in the amygdala, activation of mGluR5, but
not mGluR1, enhanced the excitatory responses of
CeLC neurons to innocuous and noxious stimuli in
naïve animals [54,55]. In the arthritis pain model, block-
a d eo fm G l u R 1a n dm G l u R 5d e c r e a s e dt h ee n h a n c e d
activity of CeLC neurons to normal-like levels, suggest-
ing a major change in the function of mGluR1 in pain.
The underlying mechanism included presynaptic facilita-
tion of excitatory transmission from the parabrachial
area and the BLA to CeLC neurons by mGluR5 under
normal conditions and by mGluR1 and mGluR5 in the
arthritis pain model [20]. Largely based on agonist data
we assumed that both mGluR1 and mGluR5 acted pre-
synaptically in that model. However, the detailed analy-
sis of miniature events in the present study suggests
that mGluR5 are postsynaptic and mGluR1 have presy-
naptic effects. The new results further show that the
action of mGluR1 on excitatory transmission involves
the inhibition of disynaptici n h i b i t o r yi n p u t sf r o mt h e
BLA (disinhibition). Inhibition of inhibitory synaptic
transmission by group I mGluRs has been shown in the
hippocampus (mGluR1 [56,57]), striatum (mGluR1 [58]),
cerebellum (mGluR1 [59]), midbrain [60,61] and peria-
queductal gray (mGluR5 [62]). The mechanism of inhi-
bition was typically presynaptic, and some evidence
suggests the involvement of retrograde endogenous can-
nabinoid signaling through CB1 receptors [62-64].
Conclusion
Both increased excitatory transmission and decreased
inhibitory transmission in the CeLC in a model of
arthritis pain involve mGluR1. These receptors act pre-
synaptically to decrease synaptic inhibition, thus dis-
inhibiting excitatory inputs to the CeLC, which may
explain the loss of inhibitory control and increase in
excitatory transmission observed in the arthritis pain
model. mGluR5 act postsynaptically to facilitate both
excitatory and inhibitory inputs, but they cannot
account for the differential pain-related changes that
involve loss of presynaptic GABAergic control of excita-
tory transmission to the CeLC. The concept of disinhibi-
tion of amygdala function may provide important
insights into emotional-affective pain mechanisms and
potential therapeutic strategies.
Methods
Animals
Male Sprague Dawley rats (120-250 g) were individually
housed in standard plastic cages (40 × 20 cm) in a tem-
p e r a t u r e - c o n t r o l l e dr o o ma n dm a i n t a i n e do na1 2h r
day/night cycle. Standard laboratory chow and tap water
were available ad libitum. On the day of the experiment,
rats were transferred from the animal facility and
allowed to acclimate to the laboratory for at least 1 hr.
Arthritis pain model
In one group of rats ("arthritis”), arthritis was induced in
one knee joint as described in detail previously [65]. A
kaolin suspension (4%, 80-100 μl) was slowly injected
into the joint cavity through the patellar ligament with a
syringe and needle (1 ml,). After repetitive flexions and
extensions of the knee for 15 min, a carrageenan solu-
tion (2%, 80-100 μl) was injected into the knee joint
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5 min. This treatment paradigm reliably leads to loca-
lized inflammation and swelling of the injected knee
within 1-3 hr. The inflammation persists for up to
2 weeks. It does not spread systemically [65]. Another
group of rats ("normal”)d i dn o tr e c e i v ea n yi n j e c t i o n s
but was kept under the same conditions as the arthritis
rats before brain slices were obtained for electrophysio-
logical studies.
Electrophysiology
Amygdala slice preparation
Brain slices containing the CeA were obtained from nor-
mal rats and from arthritic rats (4-6 h after arthritis
induction) as described before [10,20,21,23]. Rats were
decapitated, and the brains quickly were dissected out
and blocked in cold (4°C) artificial cerebrospinal fluid
(ACSF). ACSF contained the following (in mM): 117
NaCl, 4.7 KCl, 1.2 NaH2PO4, 2.5 CaCl2,1 . 2M g C l 2,2 5
NaHCO3, and 11 glucose. ACSF was oxygenated and
equilibrated to pH 7.4 with a mixture of 95% O2/5%
CO2. Coronal brain slices (500 μm) were prepared using
a Vibroslice (Camden Instruments, London, UK). After
incubation in ACSF at room temperature (21°C) for at
least 1 h, a single brain slice was transferred to the
recording chamber and submerged in ACSF (31 ± 1°C),
which superfused the slice at 2 ml/min.
Whole-cell patch-clamp recording
Whole-cell voltage-clamp recordings were made from
CeLC neurons (see Figure 1A and 1B) in brain slices
from normal and arthritic rats using the “blind” patch
technique as in our previous studies [10,20,21,23]. One
neuron was recorded in each slice and 1 or 2 slices were
used per animal. Patch electrodes (4-6 MΩ tip resis-
tance) were made from borosilicate glass capillaries (1.5
and 1.12 mm, outer and inner diameter, respectively;
Drummond, Broomall, PA) pulled on a Flaming-Brown
micropipette puller (P-97/PC; Sutter Instruments,
Novato, CA). The internal solution of the recording
electrodes contained (in mM): 122 K-gluconate, 5 NaCl,
0.3 CaCl2,2M g C l 2, 1 EGTA, 10 HEPES, 5 Na2-ATP,
and 0.4 Na3-GTP, pH was adjusted to 7.2-7.3 with KOH
and osmolarity to 280 mOsm/kg with sucrose. Data
acquisition of current signals was done using a dual
four-pole Bessel filter (Warner Instruments), a low-noise
Digidata 1322 interface (Molecular Devices), an Axo-
clamp-2B amplifier (Molecular Devices) and a Pentium
personal computer. Evoked current data were acquired
a n da n a l y z e du s i n gp C L A M P 1 0s o f t w a r e( A x o nI n s t r u -
ments). Head-stage voltage was monitored continuously
on an oscilloscope to ensure precise performance of
the amplifier. Neurons were voltage-clamped at -70
(chloride reversal potential) or 0 mV (reversal potential
o fE P S C s )f o rt h es t u d yo fe x c i t a t o r ya n di n h i b i t o r y
transmission, respectively. High gigaohm seal and low
series (20 MΩ) resistances were checked throughout the
experiment (using pClamp9 membrane test function) to
ensure high-quality recordings.
Synaptic transmission
Excitatory and inhibitory postsynaptic currents (EPSCs
and IPSCs, respectively) were evoked in CeLC neurons
(held at -70 mV or 0 mV) by electrical stimulation
(150 μs square-wave pulses; S88 stimulator; Grass Instru-
ments) of BLA afferents (see Figure 1B) using a con-
centric bipolar stimulating electrode (David Kopf
Instruments). The distance between stimulation and
recording electrode was about 1 mm. Input-output rela-
tionships were obtained by increasing the stimulus inten-
sity in 0.1 mA steps. For evaluation of a drug effect on
synaptically evoked responses, the stimulus intensity was
adjusted to 80% of the intensity required for the maxi-
mum response. Spontaneous and miniature (in 1 μM
TTX) EPSCs and IPSCs were recorded at -70 and 0 mV,
respectively [23]. A fixed length of traces (5 min) was
analyzed for frequency and amplitude distributions using
MiniAnalysis program 5.3 (Synaptosoft). The root mean
square (RMS) of the background noise was computed for
each set of data. The detection threshold for an event
was set to 3-4 times the RMS value. Peaks were detected
automatically, but each detected event was then visually
inspected to avoid the inclusion of false data.
Drugs
The following drugs were used: 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7- sulfonamide disodium
salt (NBQX; non-NMDA receptor antagonist); bicuculline
(GABAA receptor antagonist); a-amino-4-carboxy-2-
methylbenzeneacetic acid (LY367385; selective mGluR1
antagonist) and 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyri-
dine hydrochloride (MTEP; selective mGluR5 antagonist).
Drugs were purchased from Tocris Cookson (Bristol,
UK). All drugs were dissolved in ACSF to their final con-
centration on the day of the experiment. Selectivity and
target concentrations have been established in the litera-
ture [40,42,52,53]. Drugs were applied to the brain slice
by gravity-driven superfusion in the ACSF. ACSF con-
tained (in mM): 117 NaCl, 4.7 KCl, 1.2 NaH2PO4, 2.5
CaCl2, 1.2 MgCl2, 25 NaHCO3, and 11 glucose. Solution
flow into the recording chamber (1 ml volume) was con-
trolled with a three-way stopcock. Drugs were applied for
at least 8-10 min to establish equilibrium in the tissue.
ACSF served as vehicle control in all experiments.
Statistical analysis
All averaged values are given as the mean ± SE. Statisti-
cal significance was accepted at the level P < 0.05.
GraphPad Prism 3.0 software (Graph-Pad Software, San
Diego, CA) was used for all statistical analysis. For
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ANOVA or two-way ANOVA was used with appropri-
ate posttests (Bonferroni to compare selected pairs of
data; Dunnett’s multiple comparison test to compare all
data to a control value). Student’s t test (paired or
unpaired when appropriate) was used to compare two
sets of data that have Gaussian distribution and similar
variances. Kolmogorov-Smirnov test was used for cumu-
lative distribution analysis of spontaneous and miniature
synaptic events (MiniAnalysis program 5.3, Synaptosoft
Inc., Decatur, GA).
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